| abstract |
A novel sustained release oral dosage form of R-baclofen prodrug is provided. From about 3% to about 20% by weight of (3R) -4-{[(1S) -2-methyl-1- (2-methylpropanoyloxy) propoxy, based on the total weight of the dosage form Carbonylamino} -3- (4-chlorophenyl) butanoic acid or a pharmaceutically acceptable salt thereof; from about 15% to about 40% by weight microcrystalline cellulose; from about 15% to about 40% by weight hydroxypropyl An oral tablet dosage form comprising: methylcellulose; and a release rate-controlling polymer from about 3% to about 30% by weight. [Selection figure] None |